Guggenheim Reiterates Buy Rating for Oruka Therapeutics (NASDAQ:ORKA)

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating reiterated by stock analysts at Guggenheim in a research note issued on Monday,Benzinga reports. They presently have a $125.00 price objective on the stock. Guggenheim’s target price points to a potential upside of 102.94% from the stock’s current price.

A number of other brokerages have also commented on ORKA. UBS Group boosted their price objective on Oruka Therapeutics from $50.00 to $75.00 and gave the stock a “buy” rating in a report on Monday, April 6th. Barclays boosted their target price on Oruka Therapeutics from $50.00 to $78.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 7th. Piper Sandler began coverage on Oruka Therapeutics in a research note on Thursday, December 18th. They issued an “overweight” rating and a $75.00 target price on the stock. Wedbush restated an “outperform” rating and issued a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday, March 13th. Finally, Leerink Partners boosted their target price on Oruka Therapeutics from $58.00 to $86.00 and gave the stock an “outperform” rating in a research note on Monday, March 16th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $74.90.

Oruka Therapeutics Stock Performance

ORKA traded up $2.02 during midday trading on Monday, reaching $61.60. 204,396 shares of the company were exchanged, compared to its average volume of 613,519. The company’s fifty day moving average price is $39.53 and its 200 day moving average price is $32.31. The company has a market cap of $3.05 billion, a price-to-earnings ratio of -33.09 and a beta of -0.54. Oruka Therapeutics has a one year low of $7.62 and a one year high of $64.61.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.16. As a group, sell-side analysts anticipate that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Insider Activity at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,641 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $40.91, for a total value of $312,593.31. Following the transaction, the insider owned 33,377 shares in the company, valued at approximately $1,365,453.07. This represents a 18.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $41.30, for a total value of $71,407.70. Following the completion of the transaction, the chief executive officer owned 927,309 shares in the company, valued at approximately $38,297,861.70. The trade was a 0.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 23,765 shares of company stock worth $849,575. 24.69% of the stock is owned by company insiders.

Hedge Funds Weigh In On Oruka Therapeutics

Several institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd purchased a new position in Oruka Therapeutics in the fourth quarter valued at approximately $67,000. Seven Fleet Capital Management LP purchased a new position in Oruka Therapeutics in the fourth quarter valued at approximately $159,000. Invesco Ltd. lifted its stake in Oruka Therapeutics by 777.1% in the fourth quarter. Invesco Ltd. now owns 143,121 shares of the company’s stock valued at $4,338,000 after purchasing an additional 126,803 shares during the last quarter. Virtus Investment Advisers LLC purchased a new stake in shares of Oruka Therapeutics during the fourth quarter worth $267,000. Finally, RTW Investments LP lifted its position in shares of Oruka Therapeutics by 5.8% during the fourth quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock worth $62,382,000 after acquiring an additional 112,499 shares in the last quarter. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.